This press release contains information about Chemed’s EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed’s financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company’s operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed’s management similarly uses EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed’s management to estimate the resources required to meet Chemed’s future financial obligations and expenditures. Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed’s net income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION

Statements in this press release contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods and are based upon assumptions subject to certain known and unknown risks, uncertainties, contingencies and other factors, including, but not limited to, the impact of laws and regulations on Chemed’s operations, including Medicare Cap and Medicare reimbursement rates, Chemed’s estimates of the effect of Medicare Cap on VITAS’ revenues and future prospects, Chemed’s expectations regarding VITAS’ patient mix and Chemed’s expectations regarding demand for Roto-Rooter’s services.

Because forward looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Chemed’s control. Chemed’s actual results and financial condition may differ materially from those indicated in the forward-looking statements included in this press release, including as a result of the risks described above and those described in the Chemed’s Annual Report on Form 10-K for the year ended December 31, 2024 and in its Quarterly Reports filed in 2025. Any forward-looking statement made by Chemed in this press release is based only on information currently available to Chemed and speaks only as of the date on which it is made. Chemed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)(unaudited)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Service revenues and sales	$	624,900	$	606,181	$	1,890,641		1,791,294
Cost of services provided and goods sold		427,993		396,187		1,292,628		1,171,064
Selling, general and administrative expenses (aa)		105,775		101,981		311,685		320,109
Depreciation		13,664		13,147		40,798		39,601
Amortization		2,570		2,550		7,713		7,617
Other operating expense		148		159		225		288
Total costs and expenses		550,150		514,024		1,653,049		1,538,679
Income from operations		74,750		92,157		237,592		252,615
Interest expense		(457)		(427)		(1,229)		(1,281)
Other income--net (bb)		9,251		9,299		13,970		28,008
Income before income taxes		83,544		101,029		250,333		279,342
Income taxes		(19,307)		(25,253)		(61,846)		(67,662)
Net income	$	64,237	$	75,776	$	188,487	$	211,680
Earnings Per Share
Net income	$	4.46	$	5.04	$	12.97	$	14.04
Average number of shares outstanding		14,394		15,025		14,535		15,082
Diluted Earnings Per Share
Net income	$	4.46	$	5.00	$	12.89	$	13.88
Average number of shares outstanding		14,409		15,168		14,620		15,253

(aa) Selling, general and administrative ("SG&A") expenses comprise (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
SG&A expenses before long-term incentive compensation
and the impact of market value adjustments related to
deferred compensation plans	$	99,288	$	93,269	$	301,600	$	287,712
Market value adjustments related to deferred
compensation trusts		6,703		5,629		6,791		16,600
Long-term incentive compensation		(216)		3,083		3,294		15,797
Total SG&A expenses	$	105,775	$	101,981	$	311,685	$	320,109

(bb) Other income--net comprises (in thousands):
	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024

Interest income	$	2,555	$	3,668	$	7,186	$	11,405
Market value adjustments related to deferred
compensation trusts		6,703		5,629		6,791		16,600
Other		(7)		2		(7)		3
Total other income--net	$	9,251	$	9,299	$	13,970	$	28,008


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)(unaudited)

	September 30,
	2025		2024
Assets
Current assets
Cash and cash equivalents	$	129,752	$	238,451
Accounts receivable less allowances		215,570		196,481
Inventories		8,238		9,899
Prepaid income taxes		7,106		14,229
Prepaid expenses		34,577		31,377
Total current assets		395,243		490,437
Investments of deferred compensation plans held in trust		136,021		126,631
Properties and equipment, at cost less accumulated depreciation		203,939		200,939
Lease right of use asset		128,362		134,111
Identifiable intangible assets less accumulated amortization		84,930		94,753
Goodwill		666,987		666,860
Other assets		8,137		55,704
Total Assets	$	1,623,619	$	1,769,435
Liabilities
Current liabilities
Accounts payable	$	48,095	$	44,938
Accrued insurance		65,733		60,308
Accrued income taxes		1,469		3,385
Accrued compensation		79,668		73,141
Short-term lease liability		42,013		42,490
Other current liabilities		55,063		40,517
Total current liabilities		292,041		264,779
Deferred income taxes		9,687		28,076
Deferred compensation liabilities		132,380		122,240
Long-term lease liability		99,461		105,416
Other liabilities		13,367		13,169
Total Liabilities		546,936		533,680
Stockholders' Equity
Capital stock		37,593		37,395
Paid-in capital		1,581,067		1,462,569
Retained earnings		2,887,123		2,639,011
Treasury stock, at cost		(3,431,475)		(2,905,430)
Deferred compensation payable in Company stock		2,375		2,210
Total Stockholders' Equity		1,076,683		1,235,755
Total Liabilities and Stockholders' Equity	$	1,623,619	$	1,769,435


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)(unaudited)

	Nine Months Ended September 30,
	2025		2024
Cash Flows from Operating Activities
Net income	$	188,487	$	211,680
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation and amortization		48,511		47,218
Stock option expense		24,374		23,933
Benefit for deferred income taxes		(16,259)		(2,245)
Noncash long-term incentive compensation		3,057		15,783
Litigation settlements		1,850		(5,750)
Noncash directors' compensation		1,123		1,282
Amortization of debt issuance costs		241		241
Changes in operating assets and liabilities, excluding
amounts acquired in business combinations:
Increase in accounts receivable		(44,403)		(14,336)
(Increase)/decrease in inventories		(45)		2,125
Increase in prepaid expenses		(8,603)		(1,173)
Increase/(decrease) in accounts payable and
other current liabilities		10,102		(19,641)
Change in current income taxes		(2,162)		(4,545)
Net change in lease assets and liabilities		(576)		(400)
Decrease/(increase) in other assets		42,048		(21,101)
Increase in other liabilities		6,355		18,348
Other sources		639		1,165
Net cash provided by operating activities		254,739		252,584
Cash Flows from Investing Activities
Capital expenditures		(46,447)		(36,770)
Proceeds from sale of fixed assets		3,751		3,060
Business combinations, net of cash acquired		(225)		(97,400)
Other uses		(468)		(281)
Net cash used by investing activities		(43,389)		(131,391)
Cash Flows from Financing Activities
Purchases of treasury stock		(256,944)		(152,049)
Proceeds from exercise of stock options		27,152		49,906
Dividends paid		(23,196)		(19,594)
Capital stock surrendered to pay taxes on stock-based compensation		(8,484)		(8,827)
Change in cash overdrafts payable		610		(15,749)
Other sources/(uses)		914		(387)
Net cash used by financing activities		(259,948)		(146,700)
Decrease in Cash and Cash Equivalents		(48,598)		(25,507)
Cash and cash equivalents at beginning of year		178,350		263,958
Cash and cash equivalents at end of period	$	129,752	$	238,451


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(in thousands)(unaudited)
							Chemed
	VITAS		Roto-Rooter		Corporate		Consolidated
2025 (a)
Service revenues and sales	$	407,741	$	217,159	$	-	$	624,900
Cost of services provided and goods sold		320,865		107,128		-		427,993
Selling, general and administrative expenses		25,236		60,672		19,867		105,775
Depreciation		5,354		8,298		12		13,664
Amortization		26		2,544		-		2,570
Other operating expense/(income)		186		(38)		-		148
Total costs and expenses		351,667		178,604		19,879		550,150
Income/(loss) from operations		56,074		38,555		(19,879)		74,750
Interest expense		(56)		(132)		(269)		(457)
Intercompany interest income/(expense)		5,685		4,030		(9,715)		-
Other income—net		61		25		9,165		9,251
Income/(loss) before income taxes		61,764		42,478		(20,698)		83,544
Income taxes		(14,993)		(10,407)		6,093		(19,307)
Net income/(loss)	$	46,771	$	32,071	$	(14,605)	$	64,237

2024 (b)
Service revenues and sales	$	391,406	$	214,775	$	-	$	606,181
Cost of services provided and goods sold		294,936		101,251		-		396,187
Selling, general and administrative expenses		25,883		57,072		19,026		101,981
Depreciation		5,063		8,071		13		13,147
Amortization		26		2,524		-		2,550
Other operating expense		97		62		-		159
Total costs and expenses		326,005		168,980		19,039		514,024
Income/(loss) from operations		65,401		45,795		(19,039)		92,157
Interest expense		(46)		(114)		(267)		(427)
Intercompany interest income/(expense)		4,920		3,656		(8,576)		-
Other income—net		62		18		9,219		9,299
Income/(loss) before income taxes		70,337		49,355		(18,663)		101,029
Income taxes		(16,851)		(11,400)		2,998		(25,253)
Net income/(loss)	$	53,486	$	37,955	$	(15,665)	$	75,776


The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(in thousands)(unaudited)

							Chemed
	VITAS		Roto-Rooter		Corporate		Consolidated
2025 (a)
Service revenues and sales	$	1,211,341	$	679,300	$	-	$	1,890,641
Cost of services provided and goods sold		954,316		338,312		-		1,292,628
Selling, general and administrative expenses		76,861		183,856		50,968		311,685
Depreciation		15,863		24,899		36		40,798
Amortization		78		7,635		-		7,713
Other operating expense/(income)		305		(80)		-		225
Total costs and expenses		1,047,423		554,622		51,004		1,653,049
Income/(loss) from operations		163,918		124,678		(51,004)		237,592
Interest expense		(150)		(394)		(685)		(1,229)
Intercompany interest income/(expense)		16,436		11,930		(28,366)		-
Other income—net		170		58		13,742		13,970
Income/(loss) before income taxes		180,374		136,272		(66,313)		250,333
Income taxes		(45,353)		(32,344)		15,851		(61,846)
Net income/(loss)	$	135,021	$	103,928	$	(50,462)	$	188,487

2024 (b)
Service revenues and sales	$	1,119,970	$	671,324	$	-	$	1,791,294
Cost of services provided and goods sold		852,347		318,717		-		1,171,064
Selling, general and administrative expenses		73,968		175,683		70,458		320,109
Depreciation		15,288		24,275		38		39,601
Amortization		79		7,538		-		7,617
Other operating expense		160		128		-		288
Total costs and expenses		941,842		526,341		70,496		1,538,679
Income/(loss) from operations		178,128		144,983		(70,496)		252,615
Interest expense		(138)		(349)		(794)		(1,281)
Intercompany interest income/(expense)		15,096		10,638		(25,734)		-
Other income—net		138		64		27,806		28,008
Income/(loss) before income taxes		193,224		155,336		(69,218)		279,342
Income taxes		(46,517)		(36,010)		14,865		(67,662)
Net income/(loss)	$	146,707	$	119,326	$	(54,353)	$	211,680


The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARIES OF EBITDA
FOR THREE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(in thousands)(unaudited)
							Chemed
	VITAS		Roto-Rooter		Corporate		Consolidated
2025
Net income/(loss)	$	46,771	$	32,071	$	(14,605)	$	64,237
Add/(deduct):
Interest expense		56		132		269		457
Income taxes		14,993		10,407		(6,093)		19,307
Depreciation		5,354		8,298		12		13,664
Amortization		26		2,544		-		2,570
EBITDA		67,200		53,452		(20,417)		100,235
Add/(deduct):
Intercompany interest expense/(income)		(5,685)		(4,030)		9,715		-
Interest income		(69)		(25)		(2,462)		(2,556)
Stock option expense		-		-		6,067		6,067
Legal settlements		2,850		-		-		2,850
Long-term incentive compensation		-		-		(216)		(216)
Other		-		-		2,665		2,665
Adjusted EBITDA	$	64,296	$	49,397	$	(4,648)	$	109,045

2024
Net income/(loss)	$	53,486	$	37,955	$	(15,665)	$	75,776
Add/(deduct):
Interest expense		46		114		267		427
Income taxes		16,851		11,400		(2,998)		25,253
Depreciation		5,063		8,071		13		13,147
Amortization		26		2,524		-		2,550
EBITDA		75,472		60,064		(18,383)		117,153
Add/(deduct):
Intercompany interest expense/(income)		(4,920)		(3,656)		8,576		-
Interest income		(59)		(18)		(3,589)		(3,666)
Stock option expense		-		-		6,038		6,038
Long-term incentive compensation		-		-		3,083		3,083
Acquisition expense		394		(8)		-		386
Adjusted EBITDA	$	70,887	$	56,382	$	(4,275)	$	122,994

The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARIES OF EBITDA
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(in thousands)(unaudited)
							Chemed
	VITAS		Roto-Rooter		Corporate		Consolidated
2025
Net income/(loss)	$	135,021	$	103,928	$	(50,462)	$	188,487
Add/(deduct):
Interest expense		150		394		685		1,229
Income taxes		45,353		32,344		(15,851)		61,846
Depreciation		15,863		24,899		36		40,798
Amortization		78		7,635		-		7,713
EBITDA		196,465		169,200		(65,592)		300,073
Add/(deduct):
Intercompany interest expense/(income)		(16,436)		(11,930)		28,366		-
Interest income		(176)		(58)		(6,952)		(7,186)
Stock option expense		-		-		24,374		24,374
Long-term incentive compensation		-		-		3,294		3,294
Legal settlements		2,850		-		-		2,850
Other		-		-		2,665		2,665
Adjusted EBITDA	$	182,703	$	157,212	$	(13,845)	$	326,070
2024
Net income/(loss)	$	146,707	$	119,326	$	(54,353)	$	211,680
Add/(deduct):
Interest expense		138		349		794		1,281
Income taxes		46,517		36,010		(14,865)		67,662
Depreciation		15,288		24,275		38		39,601
Amortization		79		7,538		-		7,617
EBITDA		208,729		187,498		(68,386)		327,841
Add/(deduct):
Intercompany interest expense/(income)		(15,096)		(10,638)		25,734		-
Interest income		(136)		(64)		(11,205)		(11,405)
Stock option expense		-		-		23,933		23,933
Long-term incentive compensation		-		-		15,797		15,797
Acquisition expense		1,302		37		-		1,339
Adjusted EBITDA	$	194,799	$	176,833	$	(14,127)	$	357,505

The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
RECONCILIATION OF ADJUSTED NET INCOME
(in thousands, except per share data)(unaudited)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Net income as reported	$	64,237	$	75,776	$	188,487	$	211,680
Add/(deduct) pre-tax cost of:
Stock option expense		6,067		6,038		24,374		23,933
Amortization of reacquired franchise rights		2,352		2,352		7,056		7,056
Long-term incentive compensation		(216)		3,083		3,294		15,797
Legal settlements		2,850		-		2,850		-
Acquisition expense		-		386		-		1,339
Other		2,665		-		2,665		-
Add/(deduct) tax impacts:
Tax impact of the above pre-tax adjustments (1)		(2,049)		(1,761)		(6,512)		(6,762)
Excess tax benefits on stock compensation		-		(389)		(513)		(4,308)
Adjusted net income	$	75,906	$	85,485	$	221,701	$	248,735

Diluted Earnings Per Share As Reported
Net income	$	4.46	$	5.00	$	12.89	$	13.88
Average number of shares outstanding		14,409		15,168		14,620		15,253

Adjusted Diluted Earnings Per Share
Adjusted net income	$	5.27	$	5.64	$	15.16	$	16.31
Average number of shares outstanding		14,409		15,168		14,620		15,253

(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.

The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
(unaudited)
	Three Months Ended September 30,						Nine Months Ended September 30,
OPERATING STATISTICS	2025			2024			2025			2024
Net revenue ($000) (c)
Homecare	$	362,405		$	338,344		$	1,072,014		$	967,981
Inpatient		33,099			29,923			100,145			89,297
Continuous care		19,946			25,799			68,222			74,295
Other		5,807			5,082			16,898			13,900
Subtotal	$	421,257		$	399,148		$	1,257,279		$	1,145,473
Room and board, net		(3,859)			(3,336)			(11,277)			(9,437)
Contractual allowances		(3,571)			(2,167)			(9,875)			(10,077)
Medicare cap allowance		(6,086)			(2,239)			(24,786)			(5,989)
Net Revenue	$	407,741		$	391,406		$	1,211,341		$	1,119,970
Net revenue as a percent of total before Medicare cap allowance
Homecare		86.0	%		84.8	%		85.3	%		84.5	%
Inpatient		7.9			7.5			8.0			7.8
Continuous care		4.7			6.5			5.4			6.5
Other		1.4			1.2			1.3			1.2
Subtotal		100.0			100.0			100.0			100.0
Room and board, net		(0.8)			(0.8)			(0.9)			(0.8)
Contractual allowances		(0.8)			(0.5)			(0.8)			(0.9)
Medicare cap allowance		(1.4)			(0.6)			(2.0)			(0.5)
Net Revenue		97.0	%		98.1	%		96.3	%		97.8	%
Days of care
Homecare		1,685,859			1,622,680			4,980,883			4,621,755
Nursing home		309,192			320,664			923,458			908,013
Respite		12,184			9,952			33,619			26,806
Subtotal routine homecare and respite		2,007,235			1,953,296			5,937,960			5,556,574
Inpatient		28,530			26,524			86,447			79,064
Continuous care		18,309			24,365			62,576			72,335
Total		2,054,074			2,004,185			6,086,983			5,707,973

Number of days in relevant time period		92			92			273			274
Average daily census ("ADC") (days)
Homecare		18,325			17,639			18,245			16,867
Nursing home		3,361			3,485			3,383			3,314
Respite		132			108			123			98
Subtotal routine homecare and respite		21,818			21,232			21,751			20,279
Inpatient		310			288			317			289
Continuous care		199			265			229			264
Total		22,327			21,785			22,297			20,832

Total Admissions		17,714			16,775			53,398			51,020
Total Discharges		17,348			16,217			52,931			48,285
Average length of stay (days)		109.7			102.0			121.9			102.2
Median length of stay (days)		18.0			18.0			18.0			17.0

ADC by major diagnosis
Cerebro		44.1	%		43.6	%		44.6	%		43.7	%
Neurological		11.6			13.3			11.8			13.3
Cancer		10.1			10.0			9.8			10.0
Cardio		15.9			16.3			16.0			16.2
Respiratory		7.7			7.1			7.4			7.2
Other		10.6			9.7			10.4			9.6
Total		100.0	%		100.0	%		100.0	%		100.0	%
Admissions by major diagnosis
Cerebro		27.1	%		28.4	%		27.6	%		27.7	%
Neurological		6.9			7.7			6.8			7.9
Cancer		26.6			25.7			25.9			25.1
Cardio		14.3			15.1			14.7			15.7
Respiratory		10.5			9.5			10.9			9.9
Other		14.6			13.6			14.1			13.7
Total		100.0	%		100.0	%		100.0	%		100.0	%

Estimated uncollectible accounts as a percent of revenues		0.9	%		0.6	%		0.8	%		0.9	%

Accounts receivable --
Days of revenue outstanding-excluding unapplied Medicare payments		37.5			37.5			n.a.			n.a.
Days of revenue outstanding-including unapplied Medicare payments		34.0			35.5			n.a.			n.a.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
FOOTNOTES TO FINANCIAL STATEMENTS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(unaudited)

(a)	Included in the results of operations for 2025 are the following significant credits/(charges) which may not be indicative of ongoing operations
	(in thousands):
		Three Months Ended September 30, 2025
		VITAS		Roto-Rooter		Corporate		Consolidated

	Stock option expense	$	-	$	-	$	(6,067)	$	(6,067)
	Legal settlements		(2,850)		-		-		(2,850)
	Amortization of reacquired franchise agreements		-		(2,352)		-		(2,352)
	Long-term incentive compensation		-		-		216		216
	Other		-		-		(2,665)		(2,665)
	Pretax impact on earnings		(2,850)		(2,352)		(8,516)		(13,718)
	Income tax benefit on the above		698		546		805		2,049
	After-tax impact on earnings	$	(2,152)	$	(1,806)	$	(7,711)	$	(11,669)

		Nine Months Ended September 30, 2025
		VITAS		Roto-Rooter		Corporate		Consolidated

	Stock option expense	$	-	$	-	$	(24,374)	$	(24,374)
	Amortization of reacquired franchise agreements		-		(7,056)		-		(7,056)
	Long-term incentive compensation		-		-		(3,294)		(3,294)
	Legal settlements		(2,850)		-		-		(2,850)
	Other		-		-		(2,665)		(2,665)
	Pretax impact on earnings		(2,850)		(7,056)		(30,333)		(40,239)
	Excess tax benefits on stock compensation		-		-		513		513
	Income tax benefit on the above		698		1,637		4,177		6,512
	After-tax impact on earnings	$	(2,152)	$	(5,419)	$	(25,643)	$	(33,214)


(b)	Included in the results of operations for 2024 are the following significant credits/(charges) which may not be indicative of ongoing operations
	(in thousands):
		Three Months Ended September 30, 2024
		VITAS		Roto-Rooter		Corporate		Consolidated

	Stock option expense	$	-	$	-	$	(6,038)	$	(6,038)
	Long-term incentive compensation		-		-		(3,083)		(3,083)
	Amortization of reacquired franchise agreements		-		(2,352)		-		(2,352)
	Acquisition expense		(394)		8		-		(386)
	Pretax impact on earnings		(394)		(2,344)		(9,121)		(11,859)
	Excess tax benefits on stock compensation		-		-		389		389
	Income tax benefit on the above		96		546		1,119		1,761
	After-tax impact on earnings	$	(298)	$	(1,798)	$	(7,613)	$	(9,709)

		Nine Months Ended September 30, 2024
		VITAS		Roto-Rooter		Corporate		Consolidated

	Stock option expense	$	-	$	-	$	(23,933)	$	(23,933)
	Long-term incentive compensation		-		-		(15,797)		(15,797)
	Amortization of reacquired franchise agreements		-		(7,056)		-		(7,056)
	Acquisition expense		(1,302)		(37)		-		(1,339)
	Pretax impact on earnings		(1,302)		(7,093)		(39,730)		(48,125)
	Excess tax benefits on stock compensation		-		-		4,308		4,308
	Income tax benefit on the above		317		1,652		4,793		6,762
	After-tax impact on earnings	$	(985)	$	(5,441)	$	(30,629)	$	(37,055)


(c)	VITAS has 12 large (greater than 450 ADC), 22 medium (greater than 200 but less than 450 ADC) and 25 small (less than 200 ADC) hospice programs. Of Vitas' 34 Medicare provider numbers, for the current cap year, 25 provider numbers have a Medicare cap cushion of greater than 10%, four provider numbers have a Medicare cap cushion between 0% and 10%, and five provider numbers have a Medicare cap liability.